Cancer clinical trials bounce back after significant COVID-19 disruption: data from two large US cancer centers

Data from two large cancer centers in the United States have shown that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care.

Related Keywords

New York ,United States ,Ziad Bakouny ,Toni Choueiri ,Chris Labaki ,Deborah Doroshow ,Lank Center ,Tisch Cancer Institute ,Dana Farber Cancer Institute ,Mount Sinai Medical School ,Genitourinary Care ,Tisch Cancer ,Mount Sinai ,Cancer Outcomes Study ,Clinical Pharmacology ,Clinical Research ,Clinical Trial ,Disease ,Health Informatics ,Pharmaceutical Industry ,Research ,Telehealth ,Articles ,Design Of Experiments ,Treatment Of Cancer ,